Joint pain shouldn’t become an invisible price of breast cancer treatment. Aromatase inhibitors can reduce the risk of cancer returning in hormone receptor–positive breast cancer, but aching hands, knees, shoulders and hips can make daily life difficult. Exercise and acupuncture are important options. What about a prescription medicine called duloxetine? One randomized trial gives a useful answer—and a clear picture of the trade-offs.
Evidence at a glance
- Human evidence: A phase III, double-blind, placebo-controlled trial (SWOG S1202) enrolled 299 postmenopausal women with early-stage breast cancer and aromatase-inhibitor–associated joint pain.
- Benefit: Over 12 weeks, average pain was 0.82 points lower on a 0–10 scale with duloxetine than with placebo (95% confidence interval: 0.40 to 1.24 points in favor of duloxetine).
- Trade-off: Any-grade side effects were reported by 78% versus 50%, respectively. Serious grade 3 events were not statistically different between groups.
- Boundary: The study tested short-term pain relief, not cancer recurrence, survival or long-term adherence to endocrine therapy.
What did the trial actually test?
In SWOG S1202, women reported joint pain of at least 4 out of 10 that started or worsened after beginning an aromatase inhibitor. Participants were randomly assigned to duloxetine or a look-alike placebo for 13 weeks. Of 299 women enrolled, 255 were evaluable for the main pain analysis. The study was published online in November 2017 and in print in the February 2018 Journal of Clinical Oncology.
By 12 weeks, the between-group difference in average pain was 0.82 points on a ten-point scale. Other measures, including stiffness and interference with daily activities, generally favored duloxetine. This is real randomized evidence for symptom relief—but the average advantage is modest, not a dramatic disappearance of pain.
For context, investigators considered a two-point reduction from one’s own starting pain clinically meaningful. That is different from the 0.82-point difference between treatment groups. Those numbers should not be confused. Some individuals may experience important relief, while others may feel little change.
The side effects deserve equal attention
During the study, 78% of duloxetine recipients and 50% of placebo recipients reported an adverse event of any grade. The more frequent complaints in the duloxetine group included nausea, fatigue, dry mouth and headache. The proportion with grade 3 adverse events was 9% versus 4%; the difference was not statistically significant. No grade 4 or 5 events were reported in the trial.
That comparison does not mean everyone on duloxetine had a serious side effect. It does mean a treatment intended to make life easier can introduce new symptoms, so reassessment is essential. There was no clear between-group difference on the measured pain outcomes at week 24, after the study treatment had ended; durable benefit remains uncertain.
Where does duloxetine fit among the other options?
A 2025 scoping review found 74 reports of prospective studies of interventions for aromatase-inhibitor musculoskeletal symptoms. A number of approaches showed promise, but many were tested in small or uncontrolled studies, and most were short relative to the years someone might take endocrine therapy.
The Society for Integrative Oncology–ASCO guideline recommends offering acupuncture for aromatase-inhibitor–related joint pain in breast cancer. Exercise and physical therapy also have supportive evidence and may offer additional benefits for function and overall health. If symptoms remain disruptive, discussing duloxetine, other pain relief or a clinician-guided endocrine-treatment adjustment is reasonable. No one strategy is right for everyone.
Missing Script has also reviewed acupuncture for this problem and exercise during aromatase-inhibitor treatment. The useful question is not “natural or conventional?” but “which option has credible human evidence and an acceptable trade-off for me?”
A safety conversation before trying it
Duloxetine is a prescription serotonin–norepinephrine reuptake inhibitor (SNRI). A complete medication review matters. According to the US prescribing information, relevant concerns include liver disease or substantial alcohol use, interactions with serotonergic medicines, dizziness or falls, blood-pressure changes, bleeding risk with some other drugs, and low sodium in susceptible patients. It should not be stopped abruptly without a plan.
Tell the oncology team about all medicines and supplements. Duloxetine inhibits CYP2D6, a drug-processing enzyme that is relevant if tamoxifen is being used or considered; the treatment team should assess the actual regimen rather than assuming the combination is harmless or always prohibited. A new hot or swollen joint, rapidly worsening focal bone pain, or another unexplained symptom needs evaluation rather than automatic attribution to an aromatase inhibitor.
Questions to bring to your oncology team
- Does my pain pattern fit aromatase-inhibitor symptoms, or should another cause be investigated?
- Would exercise rehabilitation, acupuncture, duloxetine or a change in endocrine therapy be most appropriate for me?
- Could duloxetine interact with my current medicines or worsen another health problem?
- What change in my walking, sleep, grip strength or everyday function would count as worthwhile improvement—and when will we reassess?
The bottom line: Duloxetine has better evidence than many supplements marketed for joint pain, but its average benefit is limited and side effects are common. Getting symptoms under control matters. Do not stop an aromatase inhibitor without discussing an alternative cancer-treatment plan with your oncology team.
Primary sources and further reading
- Henry NL et al. SWOG S1202 randomized controlled trial, J Clin Oncol, 2018.
- Treatment modalities for aromatase inhibitor–associated musculoskeletal syndrome: scoping review, 2025.
- SIO–ASCO integrative pain guideline, 2022.
- Duloxetine prescribing information (DailyMed).
Missing Script is an independent educational publication. This article does not provide individual medical advice or replace consultation with your treating clinician. No drug, supplement or exercise should be started, stopped or changed based on this article alone.
Find better questions, clearer evidence: explore the Missing Script blog and subscribe to the twice-weekly newsletter.
